Ovarian Toxicity Assessment


In a paper in "The Breast" we discuss the barriers to, and facilitators of, ovarian toxicity assessment in breast cancer clinical trials.


  • Despite its importance, ovarian toxicity is rarely assessed in clinical trials
  • It is important to understand the impact of new treatment options on fertility and ovarian function
  • The main barrier to the assessment of ovarian toxicity was lack of prioritisation
  • Other barriers are resources and uncertainty regarding how to assess ovarian toxicity
  • Clinical guidelines and and stronger advocacy from key stakeholders, including regulators may facilitate more frequent inclusion in future trials

Access the Full Paper here.


GBG Forschungs GmbH
Dornhofstr. 10 | 63263 Neu-Isenburg | Fax +49 6102 7480-440

+49 6102 7480-0 | nfGBGd